Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefuroxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.86 |
| ▸ | POLB | P06746 | 2/20 | 0.86 |
| ▸ | PKM | P14618 | 2/20 | 0.86 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.59 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefuroxime SCHEMBL31472986 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL2221559 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL11243712 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL40413 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL3861498 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL1821942 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL10907122 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL11549178 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL20535121 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR | |
| Cefuroxime SCHEMBL40414 | 1.00 | TDP1 (1.00) | TDP1HSD17B10NR1I2ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34816 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260091089-A1 | Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria | CALIFORNIA INST OF TECHN (US) | 2026-04-02 | — | — | US | claimed |
| US-20260092102-A1 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | REGENERON PHARMACEUTICALS, INC. | 2026-04-02 | — | — | US | claimed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| US-4414204-A | WITH A MURAMYL-PEPTIDE | CIBA-GEIGY CORPORATION (US) | 1983-11-08 | — | — | US | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |
| EP-0083977-A1 | 6-Alpha-hydroxymethylpenicillanic acid sulfone as a beta-lactamase inhibitor | PFIZER INC. (US) | 1983-07-20 | — | — | EP | claimed |
| WO-1982003090-A1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | JAMES RICHARD | 1982-09-16 | — | — | WO | claimed |
| EP-0059645-A1 | Method and kit for identification of beta-lactamases | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-09-08 | — | — | EP | claimed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | claimed |
| US-4298732-A | Crystallization process | GLAXO GROUP LIMITED (GB) | 1981-11-03 | — | — | US | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| US-4128715-A | LYSINE SALT OF CERFUROXIME | GLAXO LABORATORIES LIMITED (GB) | 1978-12-05 | — | — | US | claimed |